Back

The impact of COVID-19 vaccines on patients with immune thrombocytopenic purpura:A protocol for a systematic review and meta-analysis

Li, Y.; Kong, D.; Ding, Y.; Wang, J.

2023-12-13 hematology
10.1101/2023.12.09.23298879 medRxiv
Show abstract

IntroductionImmune thrombocytopenic purpura (ITP) is characterized by a decrease in platelet counts and can be triggered by various factors, such as viral infections and vaccinations. Concerns have emerged regarding potential links between the vaccines for COVID-19 and the worsening of ITP. This systematic review aims to comprehensively assess the impact of COVID-19 vaccines on patients with ITP, including associated risks and outcomes. Methods and AnalysisA thorough search will be conducted across multiple electronic databases, including PubMed, Web of Science, EMBASE, Cochrane Library, CNKI, Wan Fang, VIP, and CBM, to identify pertinent studies. This study will encompass randomized controlled trials, cohort studies, case-control studies, and case series that assess the effects of COVID-19 vaccines on individuals with ITP. The primary outcome will center on alterations in platelet count, while secondary outcomes will encompass the occurrence of thromboembolic events, bleeding complications, recurrence rate of ITP, impact of ITP exacerbation, and adverse events. The data will be synthesized and subjected to meta-analysis using Review Manager Software (RevMan) V.5.3. Additionally, subgroup analyses will be conducted to investigate potential sources of heterogeneity. Ethics and disseminationSince this study involves the analysis of previously published data, ethical approval is not required. The findings will be disseminated through publication in a peer-reviewed journal and presentation at relevant scientific conferences. PROSPERO registration number CRD42023471315. Strengths and limitations of this studyO_LIAssessing the overall impact of COVID-19 vaccines on patients with ITP C_LIO_LIIncorporating a variety of study types to perform a thorough analysis C_LIO_LIImplementing a standardized methodology to evaluate and mitigate bias in the studies included C_LIO_LIPossible restrictions in data accessibility and variations in heterogeneity among the studies considered C_LIO_LIThe effects of different types of COVID-19 vaccines on patients with ITP may differ, leading to potential disparities in the outcomes. C_LI

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
British Journal of Haematology
15 papers in training set
Top 0.1%
29.4%
2
BMJ Open
554 papers in training set
Top 1%
15.3%
3
Vaccines
196 papers in training set
Top 0.3%
6.7%
50% of probability mass above
4
Frontiers in Medicine
113 papers in training set
Top 0.7%
5.2%
5
Blood Advances
54 papers in training set
Top 0.4%
4.2%
6
PLOS ONE
4510 papers in training set
Top 34%
4.2%
7
Frontiers in Immunology
586 papers in training set
Top 3%
2.9%
8
Medicine
30 papers in training set
Top 0.6%
2.8%
9
Rheumatology
21 papers in training set
Top 0.2%
2.6%
10
Blood
67 papers in training set
Top 0.6%
2.2%
11
Transactions of The Royal Society of Tropical Medicine and Hygiene
16 papers in training set
Top 0.3%
1.6%
12
BMC Public Health
147 papers in training set
Top 4%
1.4%
13
Frontiers in Pharmacology
100 papers in training set
Top 3%
1.2%
14
Journal of Clinical Medicine
91 papers in training set
Top 5%
1.2%
15
Clinical Infectious Diseases
231 papers in training set
Top 4%
1.0%
16
Infectious Diseases
14 papers in training set
Top 0.1%
1.0%
17
Frontiers in Neurology
91 papers in training set
Top 4%
1.0%
18
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.6%
0.9%
19
Transplantation
13 papers in training set
Top 0.4%
0.8%
20
International Journal of Infectious Diseases
126 papers in training set
Top 3%
0.8%
21
European Journal of Neurology
20 papers in training set
Top 0.8%
0.5%
22
Journal of Clinical Investigation
164 papers in training set
Top 8%
0.5%
23
JCI Insight
241 papers in training set
Top 9%
0.5%